StonvexLoading…
StonvexStonvexStonvexCore line items from BBIO's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $194.51M | $502.08M | $347.90M | $227.20M |
Operating Income | $-105.96M | $-523.41M | $-383.85M | $-238.65M |
Net Income | $-166.56M | $-732.94M | $-538.30M | $-353.37M |
EPS (Diluted) | $-0.84 | $-3.78 | $-2.79 | $-1.84 |
Total Assets | $1.37B | $936.02M | $998.25M | $1.08B |
Total Liabilities | $3.64B | $3.01B | $2.92B | $2.86B |
Cash & Equivalents | $879.89M | $570.12M | $642.95M | $748.95M |
Free Cash Flow OCF − CapEx | $-197.35M | $-447.01M | $-390.55M | $-280.51M |
Shares Outstanding | 195.71M | 194.77M | 192.63M | 191.16M |